Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | GNPAT | O15228 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NMT2 | O60551 | 1/20 | 0.30 |
| ▸ | NMT1 | P30419 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21154983 | 0.82 | SIRT5 (0.36) | SIRT5FOLH1OPRK1GNPATSIRT6 | |
| SCHEMBL21297373 | 0.80 | KDM4E (0.32) | FOLH1 | |
| SCHEMBL22800098 | 0.74 | KDM4E (0.35) | FOLH1OPRK1SIRT6SIRT1ITGB3 | |
| SCHEMBL15315080 | 0.74 | KISS1R (0.36) | FOLH1OPRK1SIRT6SIRT1ITGB3 | |
| SCHEMBL17642082 | 0.74 | KISS1R (0.36) | FOLH1OPRK1SIRT6SIRT1ITGB3 | |
| SCHEMBL22799569 | 0.74 | KDM4E (0.35) | FOLH1OPRK1SIRT6SIRT1ITGB3 | |
| SCHEMBL24235491 | 0.72 | KISS1R (0.34) | FOLH1SIRT6SIRT1ITGB3ITGA2B | |
| SCHEMBL16021384 | 0.72 | FOLH1 (0.47) | FOLH1 | |
| SCHEMBL20016499 | 0.72 | NMT1 (0.50) | SIRT5NMT2NMT1 | |
| SCHEMBL19700526 | 0.71 | MMP3 (0.38) | FOLH1OPRK1SIRT6SIRT1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ACOT7, COASY, LCAT | SIRT5 848/4885FOLH1 1198/4885OPRK1 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.